Dr Toni Choueiri speaks to ecancer at ESMO 2024 about new data on NKT2152 - a novel oral HIF-2α inhibitor in development for the treatment of advanced clear cell RCC (accRCC) and other tumours.

In an ongoing phase 1/2 trial safety, pharmacokinetics, pharmacodynamics and clinical efficacy were investigated in accRCC.

The study looked at 96 patients and found robust anti-tumour activity with a safety profile consistent with this class of agent.